Stemtech Corporation (OTC: STEK) has announced the launch of a new market channel, Stemtech BioSciences E-Commerce Retail, designed to expand how customers access the company’s product portfolio through a dedicated online shopping platform. The move represents a strategic step toward diversifying distribution and strengthening digital retail presence.
The new BioSciences channel is built on Shopify, providing a streamlined and user-friendly e-commerce experience. According to the company, the platform allows customers to purchase its plant-based “stemceutical™” products at retail pricing, offering direct access outside of traditional direct sales channels.
By leveraging Shopify’s infrastructure, Stemtech aims to create a scalable and accessible retail environment that supports both brand growth and customer convenience.
The BioSciences retail platform is positioned to broaden access across several product categories. These include stem cell nutrition, skin care, oral care, and pet care solutions. The company describes the initiative as a way to introduce its offerings to consumers who may prefer a traditional online retail model.
In addition to its core “stemceutical™” lines, Stemtech indicated the platform will feature complementary general health products intended to appeal to a wider audience interested in natural wellness solutions.
Company leadership emphasized that the new retail channel also supports influencer engagement. By creating a centralized online storefront, Stemtech aims to empower influencers to share product experiences more easily and generate authentic brand awareness.
This approach is intended to expand digital visibility and introduce the brand to new customer segments through social and online communities.
Beyond retail sales, Stemtech stated that the BioSciences platform is expected to serve as a lead-generation engine for its Independent Business Partners (IBPs). The company outlined plans to implement systems that allow generated leads to be acquired by IBPs, either in real time or as incentives tied to rank advancement within the direct sales structure.
This integration is designed to align the retail initiative with the company’s existing field organization.
As part of the broader rollout, Stemtech shared that it is evaluating potential incentive programs connected to the BioSciences project. These may include commission bonuses and possibly stock share rewards, reflecting the company’s status as a publicly traded entity.
Leadership noted that final structures and eligibility details are still under consideration.
The announcement also highlights that retail customers may be introduced to wholesale pricing options and the company’s home-based business opportunity. In this way, the BioSciences platform could act as an entry point for deeper engagement with the brand, offering customers the option to transition into the business model if desired.
On a GAAP basis, Sunrun reported Q4 total revenue of $1,158.8 million, representing a 124% increase year over year. Net income attributable to common stockholders was $103.6 million, translating to $0.45 basic earnings per share and $0.38 diluted earnings per share.
The company noted that part of the revenue increase reflects a transaction introduced in Q3 2025 involving sales of certain storage and solar systems linked to newly originated customer agreements, while Sunrun continues servicing those customers.
Stemtech is described as a publicly traded wellness company focused on plant-based “stemceuticals™.” The current corporation was formed in 2018 following the acquisition of operations from Stemtech International, Inc., which was originally established in 2005. The company became publicly traded in August 2021.
With the launch of Stemtech BioSciences E-Commerce Retail, Stemtech Corporation aims to expand its digital footprint, diversify customer acquisition channels, and integrate retail innovation with its direct sales foundation as it continues building its presence in the wellness sector.
Get more information
There are no reviews yet. Be the first one to write one.
